Novocure Osake

Novocure EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Novocure (NVCR) 15.8.2026 päivämäärällä on −153,80 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −170,50 M USD — muutos −9,79 % (korkeampi).

EBITDA

−153,80 MUSD

YoY

−9,79%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Novocure on 2026 −153,80 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Novocure oli 2025 −170,50 M USD. Se laskee −9,79% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Novocure Osakeanalyysi

Mitä Novocure tekee? Novocure Ltd. is a global scientific-based company that was founded in Israel in 2000. Its focus was originally on researching and developing tumor therapies. Since then, Novocure has become one of the leading companies in cancer research and treatment, specializing in the development of innovative cancer therapies. The business model of Novocure is based on developing powerful and innovative treatment methods for a variety of cancer types, including brain, pancreatic, prostate, and lung cancer. The company is committed to developing new cancer treatments that improve the lives of patients and meet their needs. Novocure also offers a wide range of products, including several treatment options based on the use of electric fields. These electric fields can specifically target the tumor and inhibit cell division without damaging the surrounding healthy tissue. This innovative technology is also called "tumor therapeutic fields" (TTF). TTF is a non-invasive procedure that is able to destroy cancer cells and inhibit the growth of cancer cells using targeted radio waves. The company also has its own research and development department dedicated to the development of innovative cancer therapies. In collaboration with numerous leading medical experts and researchers worldwide, Novocure advances cancer treatment research and development, striving to improve the treatment of cancer patients worldwide. Novocure operates three main divisions: Onco-Support, Onco-Centers, and Medical Research. The Onco-Support division offers specialized services to patients, such as training on the use of TTF devices, assistance with insurance issues, facilitating access to TTF devices, and help with setting up TTF devices. The Onco-Centers division operates various clinics specialized in the treatment of skin and brain cancer. Here, patients can benefit from the use of TTF devices and receive this therapy from experienced specialists. The Onco-Centers also provide tailored support and counseling for the needs of patients. The Medical Research division of the company also conducts research and development activities in the field of cancer therapies. Here, new therapies and procedures for cancer treatment are explored and developed, with a particular focus on the application of TTF devices. The goal of this research is to develop innovative cancer treatments that improve the lives of cancer patients and give them hope for a better future. Overall, Novocure Ltd. is an innovative and customer-oriented company dedicated to the treatment of cancer patients. The company invests heavily in research and development to develop innovative therapies and products that meet the high needs of cancer patients. The use of TTF technology is a significant step in cancer treatment, and Novocure Ltd. is leading the global development in this regard. Novocure on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Novocure osakkeesta

Yhtiön Novocure EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −153,80 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Novocure muuttui arvosta −170,50 M USD arvoon −153,80 M USD, mikä edustaa −9,79 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Novocure:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Novocure historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Novocure

Kaikki tunnusluvut — Novocure